Crescent Biopharma vs Evommune
Evommune reported revenue of $13 million in fiscal 2025, 1.2 times Crescent Biopharma's $11 million in fiscal 2025. Crescent Biopharma had an operating margin of -1407.5%, against -623.6% at Evommune. Free cash flow was −$72 million at Crescent Biopharma and −$77 million at Evommune.
Side by side
| Crescent Biopharma | Evommune | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $11M | $13M |
| Revenue growth | — | 85.7% |
| Revenue growth a year, last 5 years | 1.1% | — |
| Gross margin | — | — |
| Operating margin | −1,407.5% | −623.6% |
| Net margin | −1,419.6% | −529.8% |
| Free cash flow | −$72M | −$77M |
| Free cash flow margin | −668.1% | −589.8% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | — | 306.9% |
| Last close | $12.91 | $7.24 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | bought $30.6 million, sold $1.5 million | bought $163,610, sold $2.3 million |
| Piotroski F-score | — | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Crescent BiopharmaEvommune
Operating margin
Percent of revenue
Crescent BiopharmaEvommune
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Crescent BiopharmaEvommune
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Crescent Biopharma and Evommune pages.